» Articles » PMID: 20099346

Diffusion Tensor MRI: Preliminary Anisotropy Measures and Mapping of Breast Tumors

Overview
Date 2010 Jan 26
PMID 20099346
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate whether diffusion tensor imaging (DTI) measures of anisotropy in breast tumors are different from normal breast tissue and can improve the discrimination between benign and malignant lesions.

Materials And Methods: The study included 81 women with 105 breast lesions (76 malignant, 29 benign). DTI was performed during breast MRI examinations, and fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values were measured for breast lesions and normal tissue in each subject. FA and ADC were compared between cancers, benign lesions, and normal tissue by univariate and multivariate analyses.

Results: The FA of carcinomas (mean +/- SD: 0.24 +/- 0.07) was significantly lower than normal breast tissue in the same subjects (0.29 +/- 0.07; P < 0.0001). Multiple logistic regression showed that FA and ADC were each independent discriminators of malignancy (P < 0.0001), and that FA improved discrimination between cancer and normal tissue over ADC alone. However, there was no difference in FA between malignant and benign lesions (P = 0.98).

Conclusion: Diffusion anisotropy is significantly lower in breast cancers than normal tissue, which may reflect alterations in tissue organization. Our preliminary results suggest that FA adds incremental value over ADC alone for discriminating malignant from normal tissue but does not help with distinguishing benign from malignant lesions.

Citing Articles

Unlocking Chemotherapy Success: The Role of Diffusion Tensor Imaging in Breast Cancer Treatment.

Ciurea A, Bene I, Cheregi P, Brad T, Ciortea C, Rusu G Diagnostics (Basel). 2024; 14(23).

PMID: 39682558 PMC: 11639939. DOI: 10.3390/diagnostics14232650.


Imaging evaluation focused on microstructural tissue changes using tensor-valued diffusion encoding in breast cancers after neoadjuvant chemotherapy: is it a promising way forward?.

Cho E, Baek H, Szczepankiewicz F, An H, Jung E Gland Surg. 2024; 13(8):1387-1399.

PMID: 39282030 PMC: 11399009. DOI: 10.21037/gs-24-124.


Dual-modal Photoacoustic and Ultrasound Imaging: from preclinical to clinical applications.

Nyayapathi N, Zheng E, Zhou Q, Doyley M, Xia J Front Photon. 2024; 5.

PMID: 39185248 PMC: 11343488. DOI: 10.3389/fphot.2024.1359784.


Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.

Musall B, Rauch D, Mohamed R, Panthi B, Boge M, Candelaria R J Magn Reson Imaging. 2024; 60(4):1367-1376.

PMID: 38294179 PMC: 11289164. DOI: 10.1002/jmri.29267.


Towards detection of early response in neoadjuvant chemotherapy of breast cancer using Bayesian intravoxel incoherent motion.

Cheung S, Wu W, Senn N, Sharma R, McGoldrick T, Gagliardi T Front Oncol. 2023; 13:1277556.

PMID: 38125950 PMC: 10731248. DOI: 10.3389/fonc.2023.1277556.